Articles By Wayne Koberstein
-
Companies To Watch: Centyrex
3/1/2013
Centyrex, an entrepreneurial unit of J&J, is combining material sciences and alternative scaffolds to form novel translational drugs to meet therapeutic needs.
-
Companies To Watch: Auspex Pharmaceuticals
2/1/2013
Auspex Pharmaceuticals is a venture-financed company developing a pipeline of deuterium-based drugs in several rare to large disease areas.
-
Companies To Watch: Acetylon
1/1/2013
Acetylon’s platform of highly selective HDAC inhibitors seems to bridge several approaches in targeting a broad pathway in cancer cells by aiming at a specific HDAC.
-
Companies To Watch: Serina Therapeutics
12/3/2012
Serina Therapeutics has billed its POZ (polyoxazoline) platform as the next generation of polymer-aided drug delivery technology.
-
Companies To Watch: Aeras
11/1/2012
Aeras, not-for-profit enterprise, is the only player solely organized around a TB vaccine goal with integrated development and manufacturing in a single organization.
-
Companies To Watch: Synageva BioPharma
10/1/2012
Synageva aspires to have the mission and model of other successful orphan-drug companies but they bring an exceptional amount of industry experience and practicality to the task.
-
Companies To Watch: PsiOxus
9/3/2012
PsiOxus is exploiting novel mechanisms to fight cancer directly along with its indirect but lethal effects. In mid-July, the company landed funding for Phase 1 and 2 trials of ColoAd1, a "systemically available oncolytic vaccine" that selectively enters cancer cells and proliferates inside like a virus, killing the cells — an interesting marriage of targeted and immunotherapeutic strategies.
-
Partnering With A Big Pharma
6/28/2012
For small life science companies looking to partner with AstraZeneca’s Shaun Grady, head of strategic partnering and business development, gives advice. By Wayne Koberstein, contributing editor
-
The New Pfizer Research Strategy: Openness And Collaboration Replace The Old Imperial Model
6/28/2012
Pfizer’s new research strategy headed by Jose-Carlos Gutierrez-Ramos, has a mission to “entrepreneurialize” discovery and development and bring together three main forces in drug research: academia, biotechnology, and pharmaceuticals.. By Wayne Koberstein, contributing editor
-
Top 10 Pitfalls Of Life Sciences Partnering: Part 2
6/1/2012
The top 10 partnering pitfalls for life science companies that can ruin their chances for a successful partnership and expert advice for avoiding them.